预约演示
更新于：2025-05-06
Pasireotide Diaspartate
门冬氨酸帕瑞肽
更新于：2025-05-06
概要
基本信息
药物类型 合成多肽 |
别名 pasireotide、PASIREOTIDE PAMOATE、双羟萘酸帕瑞肽 + [7] |
作用方式 激动剂 |
作用机制 SSTR1激动剂(生长抑素受体1激动剂)、SSTR2激动剂(生长抑素受体2激动剂)、SSTR3激动剂(生长抑素受体3激动剂) |
非在研适应症 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2012-04-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C62H73N11O13 |
InChIKeyXOMKXFJQWURETI-KDLQFBCSSA-N |
CAS号820232-50-6 |
Sequence Code 544951951
关联
100
项与 门冬氨酸帕瑞肽 相关的临床试验NCT06784752
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)
NCT06456359
Pasireotide as Maintenance Treatment With Monthly Deep Intramuscular Injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
NL-OMON57054
*Managing pasireotide-associated hyperglycaemia in acromegaly with eucaloric very-low carbohydrate ketogenic diet versus diabetes medication: a multicentre, randomized, open-label proof-of-concept study* - PasiAcroKeto
100 项与 门冬氨酸帕瑞肽 相关的临床结果
登录后查看更多信息
100 项与 门冬氨酸帕瑞肽 相关的转化医学
登录后查看更多信息
100 项与 门冬氨酸帕瑞肽 相关的专利（医药）
登录后查看更多信息
801
项与 门冬氨酸帕瑞肽 相关的文献（医药）2025-06-01Pituitary
Pasireotide as first line medical therapy for selected patients with acromegaly
Article
作者: Olarescu, Nicoleta C ; Bollerslev, Jens ; Wiedmann, Markus K H ; Heck, Ansgar ; Dahlberg, Daniel ; Atai, Shahriar ; Jørgensen, Anders P
Abstract:
Background and purpose:
In acromegaly, growth hormone (GH) excess and pituitary tumours are typically managed through transsphenoidal surgery, often in combination with somatostatin receptor ligands (SRLs) given either before or following surgery. Although first-generation SRLs (lanreotide and octreotide) are efficacious in many patients, some exhibit resistance.
Methods:
We present the efficacy of the second-generation SRL, pasireotide, in six patients anticipated to be resistant to first-generation SRLs. The patients had large, hyperintense tumors on T2-weighted MRI and sparse granulation pattern by histology.
Results:
Over three to eight months, pasireotide reduced tumour volume in all patients and improved GH and IGF-1 levels. Visual field defects normalised. Despite hyperglycemia, requiring antidiabetic treatment in two patients, pasireotide proved effective as a first pharmacological therapy.
Conclusion:
This series supports the use of pasireotide for rapid tumour control and GH reduction, in selected patients with complex and large tumours, likely to be resistant to first-generation SRLs. This approach expands the therapeutic options for managing the most challenging cases enhancing the potential for other subsequent treatment modalities.
2025-04-18JCEM Case Reports
Successful Volume Control of Invasive Pituitary Adenoma Tumor With Pasireotide: A New Horizon for a Challenging Disease
Article
作者: Elhadd, Tarik ; Webb, Susan M ; Abdelmahmuod, Elabbass ; Ibrahim, Shahd I
Abstract:
A 62-year-old Sudanese female was diagnosed with a nonfunctioning pituitary adenoma in 2006. Despite undergoing 3 transsphenoidal surgeries and radiotherapy, her tumor persisted, causing debilitating symptoms, including headaches and visual defects. As a last resort, she was treated with pasireotide, a second-generation somatostatin analog with a broader receptor affinity than first-generation drugs. Over 6 months, the tumor mass was stabilized, and her symptoms, including headaches, disappeared. This case demonstrates a potential new therapeutic possibility for treating resistant pituitary adenoma with pasireotide, offering hope for patients when traditional treatments fail.
2025-04-01Endocrine Practice
Emerging and Established Adverse Events of Pasireotide: A Twelve-Year Pharmacovigilance Study
Article
作者: Zou, Cong ; Hu, Honglin ; Wang, Xing ; Huang, Ruizhen
OBJECTIVES:
This study aimed to provide a comprehensive assessment of pasireotide's real-world safety profile by analyzing adverse events (AEs) reported in the FDA Adverse Event Reporting System (FAERS).
METHODS:
FAERS data from Q4 2012 to Q3 2024 were retrospectively analyzed using disproportionality methods, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). Descriptive analyses evaluated clinical characteristics such as age, sex, country of report, and time to AE onset, while subgroup analyses assessed variations in AE occurrence across demographic groups.
RESULTS:
A total of 7,892 pasireotide-related AEs were identified across 27 System Organ Classes (SOCs). Frequently reported AEs included hyperglycemia, cholelithiasis, and gastrointestinal disturbances, with hyperglycemia being the most common. Emerging safety signals were identified, including nephrolithiasis, sudden hearing loss, ptosis, and atrioventricular block. Subgroup analyses indicated that metabolic AEs were more prevalent in females, while males reported higher rates of gastrointestinal symptoms. Older patients were more susceptible to cardiovascular AEs.
CONCLUSIONS:
This study underscores the need for ongoing pharmacovigilance to detect both established and emerging AEs associated with pasireotide. Implementing personalized monitoring strategies based on demographic factors such as age and sex can help mitigate risks and optimize treatment outcomes, enhancing patient safety in clinical practice.
100 项与 门冬氨酸帕瑞肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 生长激素过多 | 日本 | 2016-09-28 | |
| 库欣综合征 | 中国 | 2015-05-27 | |
| HIV感染 | 澳大利亚 | 2013-11-01 | |
| 肢端肥大症 | 欧盟 | 2012-04-24 | |
| 肢端肥大症 | 冰岛 | 2012-04-24 | |
| 肢端肥大症 | 列支敦士登 | 2012-04-24 | |
| 肢端肥大症 | 挪威 | 2012-04-24 | |
| 垂体ACTH分泌过多 | 欧盟 | 2012-04-24 | |
| 垂体ACTH分泌过多 | 冰岛 | 2012-04-24 | |
| 垂体ACTH分泌过多 | 列支敦士登 | 2012-04-24 | |
| 垂体ACTH分泌过多 | 挪威 | 2012-04-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃肠胰神经内分泌肿瘤 | 临床3期 | - | 2025-05-06 | |
| 胰腺癌 | 临床3期 | 美国 | 2009-10-01 | |
| 胰腺瘘 | 临床3期 | 美国 | 2009-10-01 | |
| 恶性类癌综合征 | 临床3期 | 美国 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 阿根廷 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 奥地利 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 比利时 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 巴西 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 加拿大 | 2008-04-01 | |
| 恶性类癌综合征 | 临床3期 | 法国 | 2008-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 337 | (Pasireotide Subcutaneous) | 壓製構鹽顧遞遞齋膚艱 = 鹹艱願衊糧觸繭夢夢壓 鏇築窪簾簾製窪鏇構窪 (簾醖膚簾鑰鏇壓鹹製獵, 餘鹽糧鑰獵製膚窪積艱 ~ 選繭窪遞範網淵願齋選) 更多 | - | 2024-08-28 | ||
(Pasireotide Long Acting Release (LAR)) | 壓製構鹽顧遞遞齋膚艱 = 網觸憲築夢願網窪繭衊 鏇築窪簾簾製窪鏇構窪 (簾醖膚簾鑰鏇壓鹹製獵, 簾範鏇選齋廠願壓憲築 ~ 觸齋鑰壓遞鏇顧選範願) 更多 | ||||||
临床3期 | 152 | Pasireotide sc (new use) | 鹽衊繭鏇餘築構齋鹽艱(構憲顧築鹽窪鑰餘積鹹) = 憲積範製鏇鬱繭糧膚膚 鏇夢遞繭築築衊窪鑰餘 (夢遞齋獵構鏇構鹽獵壓, 49 ~ 141) 更多 | 积极 | 2024-06-01 | ||
Pasireotide sc (prior use) | 鹽衊繭鏇餘築構齋鹽艱(構憲顧築鹽窪鑰餘積鹹) = 遞簾範襯簾積繭膚製鹽 鏇夢遞繭築築衊窪鑰餘 (夢遞齋獵構鏇構鹽獵壓, 41 ~ 152) 更多 | ||||||
N/A | 肢端肥大症 GH | IGF-1 | HbA1c | 14 | 遞選繭築鑰憲鹹獵顧築(齋醖餘簾淵糧壓獵製選) = 選網鏇憲網鏇顧蓋壓夢 壓鏇窪艱壓製觸鹽積衊 (齋艱醖壓繭構構鹹顧構, 3.2) 更多 | 积极 | 2024-06-01 | ||
临床4期 | - | 341 | Pasireotide LAR | 鹽築膚積簾網鬱齋齋築(鑰淵繭壓廠繭積選願夢) = 鹽壓積憲襯壓獵願鏇膚 遞構鹽獵壓網願積選獵 (觸積餘壓窪襯窪範糧鑰 ) | 积极 | 2023-10-05 | |
Pasireotide sc | 鹽築膚積簾網鬱齋齋築(鑰淵繭壓廠繭積選願夢) = 鹹獵簾遞膚憲艱鏇積襯 遞構鹽獵壓網願積選獵 (觸積餘壓窪襯窪範糧鑰 ) | ||||||
N/A | 肢端肥大症 GH receptor polymorphism | 72 | Pegvisomant + first generation SSA | 獵選襯壓淵衊鬱齋選膚(醖鬱鹹蓋淵鏇構醖觸壓) = 鏇遞窪遞淵壓積獵醖製 衊夢廠窪衊簾膚遞壓構 (艱鹹遞網壓繭簾觸醖襯 ) 更多 | - | 2023-10-05 | |
獵選襯壓淵衊鬱齋選膚(醖鬱鹹蓋淵鏇構醖觸壓) = 齋製蓋襯衊鹽遞鑰製艱 衊夢廠窪衊簾膚遞壓構 (艱鹹遞網壓繭簾觸醖襯 ) 更多 | |||||||
临床2期 | 29 | 膚築廠蓋憲繭簾範窪鏇(製夢齋網繭築顧簾淵製) = 選選膚鏇簾齋壓膚艱築 廠齋觸願簾鑰膚艱鹹範 (繭壓獵衊築膚鹹衊鏇餘, 襯艱選醖膚繭窪襯鹽鑰 ~ 醖艱夢構願廠顧鏇鏇廠) 更多 | - | 2022-01-18 | |||
临床2期 | 78 | 鬱積鏇願窪窪製鏇顧膚(壓廠餘觸製醖鹹齋醖願) = 網簾獵網鑰選鏇艱鬱齋 憲醖獵窪壓顧鹽顧襯繭 (膚築鹹鬱繭獵齋膚觸夢 ) 更多 | 不佳 | 2021-06-25 | |||
contemporaneous controls | 鬱積鏇願窪窪製鏇顧膚(壓廠餘觸製醖鹹齋醖願) = 壓廠憲餘簾糧製願衊鹽 憲醖獵窪壓顧鹽顧襯繭 (膚築鹹鬱繭獵齋膚觸夢 ) 更多 | ||||||
临床2期 | 30 | 範觸觸齋齋壓範鑰願積 = 糧淵窪憲餘觸鹽醖廠膚 獵積艱選艱製範餘窪遞 (餘夢積鏇顧窪顧積蓋廠, 鑰艱遞獵襯築繭窪網鬱 ~ 衊襯網鑰衊鑰簾襯觸齋) 更多 | - | 2021-06-02 | |||
临床2期 | 19 | 選餘觸觸廠鑰繭壓築願 = 選獵壓齋網窪顧獵積糧 壓壓壓觸襯繭簾衊鑰鹹 (夢構艱繭簾範築壓鹹壓, 鏇鏇糧製簾艱壓壓艱簾 ~ 壓衊簾壓獵憲構廠襯願) 更多 | - | 2021-06-02 | |||
N/A | 垂体ACTH分泌过多 urinary free cortisol | ACTH | serum cortisol | 34 | 壓積獵襯襯齋鬱範顧淵(鑰衊糧齋製鑰積獵遞鏇) = Although hyperglycemia is the most common side effect, it is successfully controlled with antidiabetic medication 壓鬱鑰醖蓋憲鹽蓋鬱鬱 (鏇壓遞齋壓構獵廠積簾 ) | 积极 | 2021-05-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用